基本信息
浏览量:2
职业迁徙
个人简介
Research interests
The Carter lab aims to take a holistic view of eukaryotic microorganisms, in particular disease-causing pathogens, with the aim of finding new ways to inhibit them and treat infections. These organims are much more closely related to humans than bacteria or viruses, making it difficult to devise treatments that don't also damage the host. Our work centres on understanding pathogen diversity using population and evolutionary genetic analysis, and on understanding cellular responses to toxins and stresses using transcriptomic and proteomic approaches. The organisms of choice are the yeast pathogens Cryptococcus neoformans, Cryptococcus gattii, Candida albicans and Candida glabrata. These organisms are commonly encountered in the environment or living on our bodies, but cause devastating illnesses, particularly in immunocompromised hosts, that are notoriously difficult to treat.
As developing new drugs is very difficult, we take the approach of enhancing existing antifungal agents with drug synergents. Natural products can be very useful in this approach, as they are often non-toxic and work via multiple mechanisms. While they may not be sufficiently potent on their own to kill pathogens, they can be combined with more traditional antimicrobials to great effect. In addition, there are approved drugs on the market that can be used in new ways in drug combinations. The modern tools of systems biology and 'omics allow us to understand how agents work on their own and in combination to a far greater level of detail than has ever been possible. We are working with bioinfomaticians and systems biology colleagues to understand the cellular pathways and processes that lead to enhanced cell death, with the aim of using these as targets in new therapies.
Our other work centres on Chromera velia, a novel photosynthetic alga that was discovered in our laboratory in 2008. Chromera holds a unique position as an intermediate between symbiotic algae that live inside the cells of corals and apicomplexan parasites including the agents of malaria and toxoplasmosis. Apicomplexans contain a relic non-photosynthetic chloroplast indicating an alga-like past; Chromera allows us to investigate how this algal ancestor may have looked and acted. We are exploring the role of Chromera in the environment, its interaction with marine organisms, particularly corals, and are also working with Medicines for Malaria Ventures to see if it can be used to develop new anti-malarial drugs.
The Carter lab aims to take a holistic view of eukaryotic microorganisms, in particular disease-causing pathogens, with the aim of finding new ways to inhibit them and treat infections. These organims are much more closely related to humans than bacteria or viruses, making it difficult to devise treatments that don't also damage the host. Our work centres on understanding pathogen diversity using population and evolutionary genetic analysis, and on understanding cellular responses to toxins and stresses using transcriptomic and proteomic approaches. The organisms of choice are the yeast pathogens Cryptococcus neoformans, Cryptococcus gattii, Candida albicans and Candida glabrata. These organisms are commonly encountered in the environment or living on our bodies, but cause devastating illnesses, particularly in immunocompromised hosts, that are notoriously difficult to treat.
As developing new drugs is very difficult, we take the approach of enhancing existing antifungal agents with drug synergents. Natural products can be very useful in this approach, as they are often non-toxic and work via multiple mechanisms. While they may not be sufficiently potent on their own to kill pathogens, they can be combined with more traditional antimicrobials to great effect. In addition, there are approved drugs on the market that can be used in new ways in drug combinations. The modern tools of systems biology and 'omics allow us to understand how agents work on their own and in combination to a far greater level of detail than has ever been possible. We are working with bioinfomaticians and systems biology colleagues to understand the cellular pathways and processes that lead to enhanced cell death, with the aim of using these as targets in new therapies.
Our other work centres on Chromera velia, a novel photosynthetic alga that was discovered in our laboratory in 2008. Chromera holds a unique position as an intermediate between symbiotic algae that live inside the cells of corals and apicomplexan parasites including the agents of malaria and toxoplasmosis. Apicomplexans contain a relic non-photosynthetic chloroplast indicating an alga-like past; Chromera allows us to investigate how this algal ancestor may have looked and acted. We are exploring the role of Chromera in the environment, its interaction with marine organisms, particularly corals, and are also working with Medicines for Malaria Ventures to see if it can be used to develop new anti-malarial drugs.
研究兴趣
论文共 140 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
npj Materials Degradationno. 1 (2023): 1-11
引用0浏览0WOS引用
0
0
biorxiv(2023)
Journal of Environmental Chemical Engineeringno. 3 (2023): 109977-109977
bioRxiv (Cold Spring Harbor Laboratory) (2023)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn